Immunohistochemistry in Renal Biopsy: Diagnostic Information Provided
Immunohistochemistry (IHC) on renal biopsies provides critical diagnostic information by detecting and characterizing immunoglobulin and complement deposits, determining their type (IgG, IgM, IgA, kappa, lambda light chains), location within renal structures, and pattern of deposition—which together establish the specific diagnosis, guide treatment decisions, and predict prognosis in glomerular diseases.
Core Diagnostic Information from IHC
Detection and Characterization of Immune Deposits
IHC serves as an alternative to immunofluorescence (IF) for detecting monoclonal immunoglobulin (MIg) deposits using antibodies against IgG, IgM, IgA, kappa, and lambda light chains 1. This technique reveals:
- Monoclonality vs. Polyclonality: Determines whether deposits are monoclonal (suggesting lymphoproliferative disorders, amyloidosis, or deposition diseases) or polyclonal (suggesting immune complex-mediated diseases)
- Light chain restriction: Identifies kappa or lambda light chain predominance, which is pathognomonic for monoclonal gammopathy-related kidney disease 1
IgG Subclass Typing: Critical Clinical Implications
When IgG deposits are identified, IgG subclass staining is mandatory because it provides both diagnostic confirmation and prognostic information 1:
- IgG3 deposits (most common): Generally associated with lower likelihood of detectable serum monoclonal protein and less frequent underlying lymphoproliferative disorder
- IgG1 deposits (second most common): Strongly associated with detectable serum monoclonal protein and underlying lymphoproliferative disorder requiring hematologic workup
This distinction fundamentally alters the clinical approach to patient evaluation and monitoring.
Specific Disease Diagnosis
IHC enables precise classification of numerous renal diseases 1:
- Monoclonal immunoglobulin deposition diseases: Cast nephropathy, AL amyloidosis, light chain deposition disease, heavy chain deposition disease
- Immune complex glomerulonephritis: Membranous nephropathy, lupus nephritis, IgA nephropathy, post-infectious glomerulonephritis
- Cryoglobulinemic glomerulonephritis
- Immunotactoid glomerulopathy
- Light-chain proximal tubulopathy
Anatomic Distribution of Deposits
IHC precisely localizes deposits to specific renal compartments 1:
- Glomeruli (mesangial, subendothelial, subepithelial, intramembranous)
- Tubular basement membranes
- Interstitium
- Arterioles and arteries
This distribution pattern is diagnostically specific and prognostically important, particularly in AL amyloidosis where extent of vascular involvement affects outcomes.
Advanced IHC Applications
Paraffin Immunofluorescence (Paraffin IF)
Paraffin IF with protease digestion is specifically recommended in three scenarios 1:
- Complement C3 glomerulopathy with circulating monoclonal protein: Unmasks hidden MIg deposits that routine IF misses
- Light-chain proximal tubulopathy: Detects intracellular light chains
- Deposits visible on electron microscopy but negative/equivocal on routine IF: Resolves discordant findings
Detection of Intracellular Immunoglobulins
IHC stains for light chains can identify intracellular monoclonal immunoglobulins when routine and pronase-digested studies are negative 1, which is particularly valuable in plasma cell dyscrasias affecting tubular epithelium.
Pattern Recognition: Distinguishing Disease Categories
Immune Complex vs. Pauci-Immune vs. Anti-GBM Disease
IHC intensity and pattern differentiate major glomerulonephritis categories 2:
- Immune complex GN: Granular deposits of IgG/IgA/IgM with C3, often with C1q
- Pauci-immune GN: Negative to 1+ staining (occasionally 2+ in necrotic areas); higher intensity suggests overlapping disease processes
- Anti-GBM disease: Intense, diffuse linear IgG staining along glomerular basement membrane with equal kappa and lambda staining
Critical Pitfalls and Limitations
Technical Considerations
- Routine panels miss IgD and IgE: Standard antibody panels detect most but not all monoclonal proteins 1
- Timing matters: Secondary nonspecific immunoglobulin insudation in chronic disease can obscure primary pathology 3
- Enzyme pretreatment variability: Paraffin-based IHC requires careful optimization of protease digestion time, which varies by specimen 4, 5
When IHC Alone Is Insufficient
Congo red staining is mandatory in all patients with serum/urine monoclonal protein to detect amyloid 1. When IF/IHC findings are equivocal for amyloid typing, mass spectrometry of laser-microdissected tissue is recommended 1.
Integration with Other Modalities
IHC findings must be correlated with:
- Light microscopy: Pattern of glomerular injury (membranoproliferative, endocapillary proliferative, membranous, etc.) 1
- Electron microscopy: Confirms electron-dense deposits, defines ultrastructure (fibrils, microtubules, organized deposits) 2
- Serum/urine studies: All MIg detected by kidney biopsy requires correlation with serum and urine testing 1
Practical Clinical Algorithm
When evaluating renal biopsy IHC results:
- Identify deposit composition: IgG, IgM, IgA, C3, C1q, kappa, lambda
- Assess for monoclonality: Light chain restriction or IgG subclass restriction
- If IgG deposits present: Perform IgG subclass staining to guide hematologic workup intensity
- Determine anatomic distribution: Glomerular location, tubular, vascular, interstitial involvement
- Correlate with clinical context: Serum/urine monoclonal protein, systemic disease, infection history
- If discordant findings: Consider paraffin IF with protease digestion or mass spectrometry
This systematic approach ensures IHC provides maximum diagnostic, prognostic, and therapeutic guidance while avoiding common interpretive errors.